Bristol Myers Squibb Says FDA Granted Accelerated Approval To Augtyro (Repotrectinib) For Patients With NTRK-Positive Locally Advanced Or Metastatic Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced that the FDA has granted accelerated approval to Augtyro (Repotrectinib) for patients with NTRK-positive locally advanced or metastatic solid tumors.

June 13, 2024 | 8:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb received FDA accelerated approval for Augtyro (Repotrectinib), which is expected to benefit patients with NTRK-positive locally advanced or metastatic solid tumors. This approval could lead to increased revenue and market share for BMY.
The FDA's accelerated approval of Augtyro (Repotrectinib) is a significant milestone for Bristol Myers Squibb. This approval allows the company to market the drug sooner, potentially increasing its revenue and market share. The news is likely to have a positive short-term impact on BMY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100